IMUX net incomeQ2 2026-$34.10M
IMUX net income was -$34.10M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$26.82M a year earlier. For the full fiscal 2025 it was -$97.17M, compared with -$100.51M in fiscal 2024.
Immunic Inc. (IMUX) financials
For the twelve months ended Jun 30, 2026, Immunic Inc. reported -$111.57M of net income.
- Net income, TTM
- -$111.57M
- Free cash flow, TTM
- -$88.05M
- Cash
- $155.10M
- Market cap
- $105.7M
FY2016FY2025
FY2016FY2025
IMUX revenue and earnings growth
IMUX EPSQ2 2026-$0.80
IMUX diluted EPS was -$0.80 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$6.20.
IMUX free cash flowQ2 2026-$31.25M
IMUX free cash flow was -$31.25M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$24.64M a year earlier. For the full fiscal 2025 it was -$85.97M, compared with -$85.03M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $81.98M | $80.05M | $83.22M | $71.25M | $61.12M | $38.64M | $22.51M | $9.60M | $39.34M | $30.05M |
| Selling, general and admin | $21.25M | $18.01M | $16.01M | $15.26M | $13.30M | $10.33M | $14.52M | $2.40M | $13.31M | $11.22M |
| Operating income | -$103.23M | -$98.05M | -$99.22M | -$119.49M | -$91.67M | -$48.97M | -$37.03M | -$12.00M | -$52.66M | -$41.27M |
| Pre-tax income | - | - | - | - | - | - | - | -$41.48M | -$52.08M | -$40.97M |
| Income tax | $0 | - | - | - | - | - | - | - | - | - |
| Net income | -$97.17M | -$100.51M | -$93.61M | -$120.41M | -$92.94M | -$44.02M | -$34.93M | -$11.54M | -$52.08M | -$40.97M |
| EPS, basic | -$6.20 | -$10.00 | -$21.10 | -$37.80 | -$39.30 | -$28.10 | -$45.20 | -$136.30 | -$13.10 | -$13.10 |
| EPS, diluted | -$6.20 | -$10.00 | -$21.10 | -$37.80 | -$39.30 | -$28.10 | -$45.20 | -$136.30 | -$13.10 | -$13.10 |
| Diluted shares | 15.6M | 10.0M | 4.4M | 3.2M | 2.4M | 1.6M | 772,226.9 | 84,695.3 | 4.0M | 3.1M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $15.48M | $35.67M | $46.67M | $106.75M | $86.86M | $127.45M | $29.37M | $13.07M | $4.50M | $59.99M |
| Current assets | $22.87M | $39.33M | $52.53M | $125.86M | $104.99M | $133.75M | $32.23M | $13.33M | $58.12M | $61.46M |
| Goodwill | - | - | - | $0 | $32.97M | $32.97M | $32.97M | $0 | - | - |
| Total assets | $24.05M | $40.87M | $54.30M | $127.75M | $139.10M | $167.86M | $65.95M | $13.37M | $60.38M | $64.03M |
| Current liabilities | $30.62M | $22.18M | $24.73M | $13.08M | $11.40M | $8.40M | $7.07M | $1.92M | $10.28M | $5.48M |
| Total liabilities | $30.73M | $22.44M | $25.37M | $14.07M | $11.98M | $9.08M | $7.59M | $1.92M | - | - |
| Shareholders' equity | -$6.67M | $18.43M | $28.93M | $113.68M | $127.11M | $158.78M | $58.36M | -$25.74M | -$13.34M | $58.45M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$85.81M | -$84.77M | -$70.83M | -$65.14M | -$83.23M | -$46.12M | -$28.55M | -$9.74M | -$40.40M | -$35.77M |
| Capital expenditures | $161.0K | $264.0K | $334.0K | $112.0K | $67.0K | $146.0K | $55.0K | $32.0K | $685.0K | $556.0K |
| Free cash flow | -$85.97M | -$85.03M | -$71.16M | -$65.26M | -$83.30M | -$46.27M | -$28.60M | -$9.77M | -$41.08M | -$36.33M |
| Investing cash flow | -$161.0K | -$264.0K | $9.46M | -$9.74M | -$67.0K | -$146.0K | $10.54M | -$32.0K | -$678.0K | -$21.0K |
| Financing cash flow | $65.58M | $74.54M | $1.03M | $95.76M | $42.84M | $144.43M | $34.90M | $19.26M | $37.98M | $12.37M |
| Stock-based compensation | $8.86M | $8.53M | $7.10M | $7.93M | $5.95M | $2.75M | $6.51M | $0 | $5.48M | $4.68M |
| Depreciation and amortization | $168.0K | $134.0K | $111.0K | $77.0K | $85.0K | $39.0K | $50.0K | $15.0K | $998.0K | $1.81M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on equity | - | -545.4% | -323.6% | -105.9% | -73.1% | -27.7% | -59.9% | - | - | -70.1% |
| Return on assets | -404.0% | -245.9% | -172.4% | -94.2% | -66.8% | -26.2% | -53.0% | -86.3% | -86.2% | -64.0% |
| Current ratio | 0.75 | 1.77 | 2.12 | 9.62 | 9.21 | 15.93 | 4.56 | 6.94 | 5.65 | 11.22 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $25.93M | $25.63M | $19.07M | $20.01M | $21.37M | $21.53M | $21.62M | $21.37M | $18.32M | $18.74M | $19.28M | $19.80M |
| Selling, general and admin | $9.40M | $7.61M | $4.26M | $5.98M | $5.71M | $5.29M | $4.01M | $4.36M | $4.49M | $5.14M | $4.10M | $3.77M |
| Operating income | -$35.33M | -$33.23M | -$23.33M | -$25.99M | -$27.08M | -$26.82M | -$25.63M | -$25.73M | -$22.81M | -$23.88M | -$23.38M | -$23.57M |
| Net income | -$34.10M | -$32.59M | -$19.30M | -$25.58M | -$26.82M | -$25.47M | -$25.18M | -$24.37M | -$21.38M | -$29.58M | -$21.57M | -$22.77M |
| EPS, basic | -$0.80 | -$1.08 | - | -$1.30 | -$2.03 | -$2.51 | -$2.50 | -$2.40 | -$2.10 | -$3.00 | -$4.80 | -$5.10 |
| EPS, diluted | -$0.80 | -$1.08 | - | -$1.30 | -$2.03 | -$2.51 | -$2.50 | -$2.40 | -$2.10 | -$3.00 | -$4.80 | -$5.10 |
| Diluted shares | 42.5M | 30.1M | - | 19.4M | 13.2M | 10.1M | - | 10.1M | 10.1M | 9.7M | - | 4.5M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $155.10M | $186.63M | $15.48M | $35.13M | $55.31M | $14.30M | $35.67M | $59.07M | $79.70M | $97.31M | $46.67M | $59.69M |
| Current assets | $157.83M | $188.76M | $22.87M | $39.27M | $59.84M | $18.98M | $39.33M | $63.27M | $84.98M | $102.61M | $52.53M | $65.23M |
| Total assets | $159.17M | $189.74M | $24.05M | $40.70M | $61.43M | $20.52M | $40.87M | $64.76M | $86.49M | $104.16M | $54.30M | $66.98M |
| Current liabilities | $31.26M | $38.36M | $30.62M | $30.08M | $27.31M | $25.59M | $22.18M | $23.36M | $22.68M | $20.15M | $24.73M | $17.78M |
| Total liabilities | $31.59M | $38.51M | $30.73M | $30.20M | $27.52M | $25.80M | $22.44M | $23.54M | $22.92M | $20.58M | $25.37M | $18.57M |
| Shareholders' equity | $127.58M | $151.23M | -$6.67M | $10.50M | $33.91M | -$5.29M | $18.43M | $41.22M | $63.57M | $83.58M | $28.93M | $48.41M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$31.00M | -$17.30M | -$19.28M | -$20.14M | -$24.61M | -$21.78M | -$22.96M | -$20.80M | -$17.04M | -$23.97M | -$14.03M | -$17.31M |
| Capital expenditures | $249.0K | $2.0K | $11.0K | $67.0K | $36.0K | $47.0K | $3.0K | $50.0K | $180.0K | $31.0K | $165.0K | $44.0K |
| Free cash flow | -$31.25M | -$17.30M | -$19.29M | -$20.21M | -$24.64M | -$21.82M | -$22.97M | -$20.84M | -$17.22M | -$24.00M | -$14.19M | -$17.36M |
| Investing cash flow | -$249.0K | -$2.0K | -$11.0K | -$67.0K | -$36.0K | -$47.0K | -$3.0K | -$50.0K | -$180.0K | -$31.0K | -$165.0K | -$44.0K |
| Financing cash flow | $118.0K | $188.64M | $59.0K | $0 | $65.52M | $0 | $77.0K | $0 | $0 | $74.46M | $604.0K | $282.0K |
| Stock-based compensation | $6.78M | $4.47M | $1.31M | $3.61M | $1.90M | $2.04M | $1.99M | $1.91M | $1.88M | $2.75M | $1.64M | $1.69M |
| Depreciation and amortization | $34.0K | $33.0K | $42.0K | $40.0K | $43.0K | $43.0K | $35.0K | $42.0K | $31.0K | $26.0K | $23.0K | $34.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 5.05 | 4.92 | 0.75 | 1.31 | 2.19 | 0.74 | 1.77 | 2.71 | 3.75 | 5.09 | 2.12 | 3.67 |
Source: XBRL data Immunic Inc. files with the SEC, latest filing dated Aug 11, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported May 13, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
IMUX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| IMUX | - | - | -$111.57M | - | $105.7M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
IMUX FAQ
5 questionsIs IMUX profitable?
No. Immunic Inc. reported a net loss of $111.57M for the twelve months ended Jun 30, 2026.How much cash and debt does IMUX have?
Immunic Inc. reported $155.10M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is IMUX free cash flow?
Immunic Inc. generated -$88.05M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$87.72M less capital expenditures.When did IMUX last report financial results?
The latest statements here come from Immunic Inc.'s 10-Q filed on Aug 11, 2026, covering the period ended Jun 30, 2026.Where does this IMUX financial data come from?
Quantisnow builds these statements from the structured XBRL data Immunic Inc. files with the SEC. It is provided for information only and is not investment advice.